Clinical Trials Logo

Clinical Trial Summary

This study is designed to compare the effects of COREG MR (carvedilol modified release formulation) to atenolol on indices of left ventricular dimensions when added to standardized angiotensin converting enzyme (ACE) inhibition, and to the effect of ACE inhibition alone. Subjects with LVH (left ventricular hypertrophy) and hypertension will be studied. The primary endpoint will be the change in left ventricular mass index (LVMI) characterized by magnetic resonance imaging (MRI) following 12 months of treatment. Secondary endpoints include the change in LV (left ventricular) mass, LV wall thickness, diastolic left ventricular filling parameters, and left ventricular ejection fraction by echocardiographic methods at Treatment Month 12. Composite outcomes and individual event data will also be evaluated by treatment group.


Clinical Trial Description

A Randomized, Double-Blind, Multi-Center Study Comparing the Effects of Carvedilol Modified Release Formulation (COREG MR) and Atenolol in Combination with and Compared to an Angiotensin Converting Enzyme Inhibitor (Lisinopril) on Left Ventricular Mass Regression in Hypertensive Patients with Left Ventricular Hypertrophy (LVH). ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00108082
Study type Interventional
Source GlaxoSmithKline
Contact
Status Completed
Phase Phase 3
Start date January 2005
Completion date August 2008

See also
  Status Clinical Trial Phase
Completed NCT02237339 - Does Allopurinol Reduce Thickening of the Left Ventricle of the Heart in Patient With Treated Hypertension? Phase 4
Completed NCT00041418 - Cardiac MR of Subclinical CVD: Impact of Age N/A
Completed NCT00005373 - Racial Differences in the Coronary Microcirculation N/A
Recruiting NCT00989508 - Myocardial Protection With Perhexiline in Left Ventricular Hypertrophy Phase 2/Phase 3
Completed NCT03482934 - Predictors of Left Ventricular Hypertrophy in Hypertensive Patients in Assiut Governorate
Completed NCT03415750 - Everolimus and Tacrolimus Combination for Regression of Left Ventricular Hypertrophy in Renal Transplants Phase 4
Completed NCT02973607 - Effects of a Reduction in Renal Function on Cardiovascular Structure and Function
Completed NCT03749551 - Towards Understanding the Phenotype of Cardiovascular Disease in CKD - TRUE-Type-CKD Study
Completed NCT01976689 - New-onset Diabetes and Left Ventricular Hypertrophy in Renal Transplantation N/A
Active, not recruiting NCT05713916 - Effect of a Targeted Notification and Clinical Support Pathway on Individuals With Left Ventricular Hypertrophy N/A
Recruiting NCT00552851 - Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Phase 4
Active, not recruiting NCT03094143 - Early Valve Replacement Guided by Biomarkers of LV Decompensation in Asymptomatic Patients With Severe AS N/A
Completed NCT02444689 - EMPower: Electronic Media Powering Positive Health Changes in Youth N/A
Terminated NCT00616902 - The PRIMO II Study: Paricalcitol Injection Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease (CKD) Stage 5 Phase 3
Withdrawn NCT03315832 - Efficacy of Angiotensin Receptor Blocker Following aortIc Valve Intervention for Aortic STenOsis: a Randomized mulTi-cEntric Double-blind Phase II Study Phase 2/Phase 3
Completed NCT03180593 - Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH Phase 4
Completed NCT01144039 - Glutamate and Diastolic Function in Patients Undergoing Aortic Valve Repair Phase 4
Completed NCT00045994 - The SILVER Study: Systolic Hypertension Interaction With Left Ventricular Remodeling Phase 2
Active, not recruiting NCT02599480 - Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure Phase 2
Active, not recruiting NCT04862273 - Native T1 CMR Imaging for Diagnosis of Cardiac Amyloidosis